Parkinson's disease dementia

UT Health Science Center San Antonio recognized as Parkinson's Foundation Comprehensive Care Center

Retrieved on: 
Tuesday, August 1, 2023
Workforce, Huntington's disease, Deep brain stimulation, Hallucination, University, Center of excellence, Tic, Parkinson's Foundation, University of Texas System, University of Texas Health Science Center at San Antonio, Senior counsel, DSM-IV codes, Therapy, Health, Parkinson's disease dementia, Quality of life, UT Health San Antonio Cancer Center, Research, Brain, Neurology, Department of Neurology, Xuanwu hospital, Dystonia, Bone, Movement, Teaching hospital, Essential tremor, Pain, Social, DBS, Electrode, Parkinson's disease, Neurosurgery, MD, Patient, SAN, Person-centered therapy, Rush Alzheimer's Disease Center, Long School, Long School of Medicine, Movement disorder, Bleeding, Memory, Skin, Disease, Pharmaceutical industry, Nursing, Veterinary medicine, Dentistry, Central Texas

SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.

Key Points: 
  • Advanced multidisciplinary care for Parkinson's disease is available at The University of Texas Health Science Center at San Antonio, which this summer was named a Parkinson's Foundation Comprehensive Care Center.
  • SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.
  • The UT Health San Antonio Movement Disorders Center is also recognized as a Huntington's Disease Center of Excellence and provides comprehensive care for patients with Huntington's disease.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.

Parkinsonian Symptoms -- Capturing a Comprehensive Picture with Fit-for-Purpose Assessments, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, April 5, 2023
Drug development, Parkinson's disease dementia, Bureau of Oceans and International Environmental and Scientific Affairs, Multiple system atrophy, Disease, DLB, PDD, Doctor of Philosophy, Parkinson's disease, Patient, MSA, Three-body problem, CBD, Disability studies, PSP, Safety, Medical device, Pharmaceutical industry, Cogstate Brief Battery, Dementia, Parkinsonism

TORONTO, April 5, 2023 /PRNewswire-PRWeb/ -- This webinar will discuss key considerations for instrument selection, data quality assurance and innovative enabling technologies for evaluating Parkinsonian symptoms.

Key Points: 
  • In this free webinar, learn about the key considerations for instrument selection, data quality assurance and innovative enabling technologies for evaluating Parkinsonian symptoms.
  • TORONTO, April 5, 2023 /PRNewswire-PRWeb/ -- This webinar will discuss key considerations for instrument selection, data quality assurance and innovative enabling technologies for evaluating Parkinsonian symptoms.
  • People with Parkinson's disease or parkinsonian conditions suffer from a range of symptoms, the most apparent of which may be motor impairment.
  • Join this webinar to learn how digital assessments and enabling technologies help gain a comprehensive understanding of Parkinsonian symptoms, reflective of importance to patients, across motor, cognitive & behavioral impairments.

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Retrieved on: 
Wednesday, December 14, 2022
Parkinson's disease, Coronavirus Scientific Advisory Board (Turkey), Associate, Specialist, Diagnosis, Annual report, Research, Nature, CNS, School, Parkinson's disease dementia, Grimmer, Degenerative disease, Cancer, Central nervous system disease, Central nervous system, Pain, Doctor of Philosophy, Epilepsy, Mouse, Government budget balance, PET, Amyloid, Psychiatry, MD, Neurodegeneration, The Michael J. Fox Foundation, Institute of technology, Growth, Biomarker, Office of the National Coordinator for Health Information Technology, Rett syndrome, Patient, Therapy, Medical device, Pharmaceutical industry, Psychotherapy, Alzheimer's disease

Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study.

Key Points: 
  • Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study.
  • The main focus of Prof. Dr. Grimmer’s research is assessing the usefulness of biomarkers in predicting neurocognitive disorders.
  • In addition, he has served as a national coordinating investigator and as a principal investigator in more than 70 drug trials including all monoclonal antibodies against cerebral amyloid load.
  • “I’m excited to join Anavex’s Scientific Advisory Board at this time of important growth and evolution of the Company,” said Professor Dr. Grimmer.

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 12, 2022
Conference, Parkinson's disease, Pacific Ocean, Annual report, Research, Nature, CNS, AM, Parkinson's disease dementia, Westin St. Francis, Degenerative disease, Cancer, Central nervous system disease, Central nervous system, Pain, Government budget balance, Doctor of Philosophy, Epilepsy, Mouse, Amyloid, The Michael J. Fox Foundation, Rett syndrome, Patient, Therapy, Pharmaceutical industry, Alzheimer's disease

Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM - 08:55 AM (Pacific Time).

Key Points: 
  • Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM - 08:55 AM (Pacific Time).
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • About Anavex Life Sciences Corp.
    Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Retrieved on: 
Friday, December 2, 2022
Degenerative disease, Therapy, Mouse, The Michael J. Fox Foundation, Conference, Central nervous system, Government budget balance, Parkinson's disease, Research, Patient, Parkinson's disease dementia, Cancer, Epilepsy, Central nervous system disease, Annual report, Rett syndrome, Pain, Webcast, Amyloid, Conference call, Nature, Web conferencing, CNS, Pharmaceutical industry, Alzheimer's disease

Webcast / Conference Call Information:

Key Points: 
  • Webcast / Conference Call Information:
    The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the Webinar ID: 815 1815 0021 reference passcode 279853.
  • A replay of the conference call will also be available on Anavexs website for up to 30 days.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Retrieved on: 
Friday, December 2, 2022
Principal investigator, Congress, Safety, Amyloid, ITT, Nature, Research, Cancer, Clinical trial, Neurodegeneration, Dizziness, Parkinson's disease dementia, Patient, MCI, Caregiver, Drug development, Dementia, Quality of life, Mouse, Government budget balance, ADAS-Cog, Nursing, Parkinson's disease, Central nervous system, CNS, Trial of the century, Annual report, Met, SIGMAR1, Cognition, The Michael J. Fox Foundation, Degenerative disease, Epilepsy, ECG, Central nervous system disease, Pain, AD, Death, Hospice, MPH, FRANZCP, Incidence, Communication, Rett syndrome, Therapy, Vital signs, Odds ratio, Clinical Dementia Rating, Medical imaging, Pharmaceutical industry, Fine chemical, Vaccine, Alzheimer's disease, Doctor of Philosophy, MD

ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.

Key Points: 
  • ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
  • ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
  • On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

Retrieved on: 
Wednesday, November 23, 2022
Epilepsy, Parkinson's disease dementia, Nature, Parkinson's disease, Conference, Amyloid, Pain, Degenerative disease, Patient, Central nervous system disease, Annual report, Research, Central nervous system, Government budget balance, CNS, Webcast, Mouse, Cancer, The Michael J. Fox Foundation, Therapy, Rett syndrome, Conference call, Pharmaceutical industry, Alzheimer's disease

Management will host a conference call on Monday November 28, 2022, at 8:30 am ET to review financial results and provide an update on the execution of the Companys growth strategy.

Key Points: 
  • Management will host a conference call on Monday November 28, 2022, at 8:30 am ET to review financial results and provide an update on the execution of the Companys growth strategy.
  • Webcast / Conference Call Information:
    The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the reference passcode 511901.
  • A replay of the conference call will also be available on Anavexs website for up to 30 days.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

Retrieved on: 
Tuesday, November 8, 2022
Investor, GLOBE, Adult, Nature, Doctor of Philosophy, St. Regis New York, Parkinson's disease, Central nervous system disease, The Michael J. Fox Foundation, Research, Rett syndrome, Epilepsy, St. Regis Hotels & Resorts, Mouse, Neurology, SEC, Annual report, Guggenheim, Degenerative disease, Cancer, Conference, Amyloid, Pain, Patient, Government budget balance, Therapy, Parkinson's disease dementia, Central nervous system, CNS, Pharmaceutical industry, Facebook, Alzheimer's disease

A live audio webcast will be accessible through the Investors section of the Companys website at www.anavex.com .

Key Points: 
  • A live audio webcast will be accessible through the Investors section of the Companys website at www.anavex.com .
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.